OXFORD, UNITED KINGDOM--(Marketwire - September 29, 2011) - Mirada Medical has integrated its multi-modal Deformable Fusion technology into Varian's SmartAdapt application and will present a study assessing the efficacy of the technology for MR to CT deformable registration at the annual meeting of the American Society for Radiation Oncology (ASTRO) in Miami, Florida.
Mirada will also be showcasing a new range of software planning tools in their exhibit (Booth #1257) that incorporate its fusion technologies to support: dose warping, dose summation, atlas based auto-contouring, deformable fusion of multi-sequence MR, PET and SPECT and single click contour warping to support adaptive re-planning.
"We are proud that our industry leading registration technology has been incorporated into Varian's SmartAdapt. The validation study demonstrates that diagnostic or treatment position MR can be reliably aligned to CT planning images," says Dr. Timor Kadir, Mirada Chief Science and Technology Officer. "This technology brings the benefit of MRI's unrivalled soft tissue differentiation into conventional CT based planning."
Dr. Mark Gooding, senior scientist at Mirada, will present the study and poster presentation (#3262) at ASTRO. The study was chosen from a record breaking 2,437 abstracts submitted for review to be presented. ASTRO is the largest gathering of radiation oncology specialists in the world.
The study, titled "Assessing the quality of deformable CT-MR registration for the purpose of multi-modal radiotherapy planning," examines the performance of Mirada's multi-modal deformable registration algorithm for the fusion of head and neck, prostate and cervical diagnostic MR scans to CT planning volumes. Performance was assessed by experts in radiation oncology from four independent clinical institutions and quantitative errors were also measured using landmarks. In all cases, deformable registration significantly improved the alignment between MR and planning CT, approximately halving the registration error compared to conventional rigid alignment. The clinical experts' assessment concluded that the results required minimal intervention prior to use in multi-modal contouring.
About Mirada Medical
Mirada Medical is an internationally recognised brand in advanced medical imaging. The company develops high value clinical software applications, which are used across diagnostic radiology, nuclear medicine, radiation oncology, tumor board and elsewhere.
Mirada specializes in simplifying technically complex image processing tasks, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention.
Mirada was originally spun out of the University of Oxford. The company's technologies are, to this day, developed by a team of dedicated engineers and world-renowned scientists working out of Oxford, England.
Mirada's products have been designed to ease the deployment of these powerful technologies into any hospital or imaging center workflow. Mirada's applications can be delivered using thin client or cloud based architectures, or licensed on a floating or per workstation basis. Most recently, Mirada has focused on the development of disease specific solutions for use across departments working with patients to fight cancer. In particular, Mirada's powerful image registration technologies have been tuned to the needs of radiation oncology, and quantification technologies have been redefined to optimize support for standard protocols such as RECIST and PERCIST. In addition, powerful imaging solutions have been introduced to support better collaborative working, in particular in the context of a rich web-based viewer for referring physicians and a robust solution for presentation of images at multidisciplinary meetings such as tumor board.
Mirada Medical, Mirada XD3 and Casemeeting are all trademarks of Mirada Medical Ltd.
For more information, visit www.mirada-medical.com
PDF of release: http://hugin.info/143183/R/1550717/477469.pdf